In people with Parkinson's disease, neuropsychiatric signs and symptoms are common
throughout the disease course. These symptoms can be disabling and as clinically relevant …

Abstract Monoamine oxidase-B (MAO-B) inhibitors are commonly used for the symptomatic
treatment of Parkinson's disease (PD). MAO-B inhibitor monotherapy has been shown to be …

Bradykinesia is one of the cardinal motor symptoms of Parkinson's disease and other
parkinsonisms. The various clinical aspects related to bradykinesia and the …

Deriving disease subtypes from electronic health records (EHRs) can guide next-generation
personalized medicine. However, challenges in summarizing and representing patient data …

Exercise is increasingly being recognized as a key element in the overall management of
persons living with Parkinson's disease (PD) but various (disease-specific) barriers may …

ABSTRACT Purpose: In the United States, nearly one million people are diagnosed with
Parkinson Disease (PD). The ratio of PD is kept increasing as compared to the combined …

Abstract Background Subjective cognitive complaints (SCCs) in Parkinson's disease (PD)
are reported frequently, but their prevalence and association with changes on objective …

Following an acute COVID-19 infection, a large number of patients experience persisting
symptoms for more than four weeks, a condition now classified as Long-COVID syndrome …

The high fall rate of the elderly brings enormous challenges to families and the medical
system; therefore, early risk assessment and intervention are quite necessary. Compared to …

Background: Parkinson's disease (PD) is a neurodegenerative condition with a diverse and
complex pattern of motor and non-motor symptoms which change over time with disease …